Cerevel Therapeutics GAAP EPS of -$0.40

Mar. 01, 2022 6:33 AM ETCerevel Therapeutics Holdings, Inc. (CERE)By: Meghavi Singh, SA News Editor
  • Cerevel Therapeutics press release (NASDAQ:CERE): Q4 GAAP EPS of -$0.40.
  • Cash, cash equivalents and marketable securities as of December 31, 2021, were $618.0 million, compared to $383.6 million as of December 31, 2020.
  • Financial Outlook: The Company anticipates R&D expenses for 2022 to increase relative to 2021, driven by initiation of the comprehensive Phase 2 program for emraclidine.
  • Cerevel expects G&A expenses for 2022 to increase relative to 2021 to support the expansion and advancement of its pipeline and initiate pre-commercialization activities.
  • The Company’s cash, cash equivalents and marketable securities are expected to continue to support operations into 2024.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.